Prostate-Specific Antigen

"Prostate-Specific Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.

Descriptor ID	D017430
MeSH Number(s)	D08.811.277.656.300.760.442.750 D08.811.277.656.959.350.442.750 D12.776.866.249.500 D23.050.285.625 D23.101.140.625
Concept/Terms	Prostate-Specific Antigen Prostate-Specific Antigen gamma-Seminoprotein gamma Seminoprotein Prostate Specific Antigen hK3 Kallikrein Kallikrein, hK3 Semenogelase Kallikrein hK3 Seminin

Below are MeSH descriptors whose meaning is more general than "Prostate-Specific Antigen".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Hydrolases [D08.811.277]
Peptide Hydrolases [D08.811.277.656]
Endopeptidases [D08.811.277.656.300]
Serine Endopeptidases [D08.811.277.656.300.760]
Kallikreins [D08.811.277.656.300.760.442]
Prostate-Specific Antigen [D08.811.277.656.300.760.442.750]
Serine Proteases [D08.811.277.656.959]
Serine Endopeptidases [D08.811.277.656.959.350]
Kallikreins [D08.811.277.656.959.350.442]
Prostate-Specific Antigen [D08.811.277.656.959.350.442.750]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Seminal Plasma Proteins [D12.776.866]
Prostatic Secretory Proteins [D12.776.866.249]
Prostate-Specific Antigen [D12.776.866.249.500]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Neoplasm [D23.050.285]
Prostate-Specific Antigen [D23.050.285.625]
Biomarkers [D23.101]
Biomarkers, Tumor [D23.101.140]
Prostate-Specific Antigen [D23.101.140.625]

Below are MeSH descriptors whose meaning is related to "Prostate-Specific Antigen".

Below are MeSH descriptors whose meaning is more specific than "Prostate-Specific Antigen".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Prostate-Specific Antigen" by people in this website by year, and whether "Prostate-Specific Antigen" was a major or minor topic of these publications.

Bar chart showing 38 publications over 21 distinct years, with a maximum of 4 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	0	1
1996	1	1	2
2003	0	2	2
2004	2	1	3
2005	0	1	1
2006	1	0	1
2007	2	1	3
2008	0	4	4
2009	1	0	1
2010	0	1	1
2011	2	0	2
2012	1	1	2
2013	1	0	1
2014	2	0	2
2015	0	1	1
2016	1	2	3
2017	1	1	2
2018	0	1	1
2019	0	1	1
2020	2	1	3
2022	0	1	1

Below are the most recent publications written about "Prostate-Specific Antigen" by people in Profiles.

Epstein MM, Sundaresan D, Fair M, Fouayzi H, Warner ET, Garber LD, Gurwitz JH, Field TS. Trends in breast and prostate cancer screening and diagnostic procedures during the COVID-19 pandemic in central Massachusetts. Cancer Causes Control. 2022 Oct; 33(10):1313-1323.

View in: PubMed
Sohlberg EM, Thomas IC, Yang J, Kapphahn K, Velaer KN, Goldstein MK, Wagner TH, Chertow GM, Brooks JD, Patel CJ, Desai M, Leppert JT. Laboratory-wide association study of survival with prostate cancer. Cancer. 2021 04 01; 127(7):1102-1113.

View in: PubMed
Johnson JA, Moser RP, Ellison GL, Martin DN. Associations of Prostate-Specific Antigen (PSA) Testing in the US Population: Results from a National Cross-Sectional Survey. J Community Health. 2021 04; 46(2):389-398.

View in: PubMed
Frendl DM, Epstein MM, Fouayzi H, Krajenta R, Rybicki BA, Sokoloff MH. Prostate-specific antigen testing after the US Preventive Services Task Force recommendation: a population-based analysis of electronic health data. Cancer Causes Control. 2020 Sep; 31(9):861-867.

View in: PubMed
Andrews DB, Lalani T. Patient-Friendly Summary of the ACR Appropriateness Criteria: Prostate Cancer-Pretreatment Detection, Surveillance, and Staging. J Am Coll Radiol. 2019 Jan; 16(1):e1.

View in: PubMed
Farina NH, Zingiryan A, Vrolijk MA, Perrapato SD, Ades S, Stein GS, Lian JB, Landry CC. Nanoparticle-based targeted cancer strategies for non-invasive prostate cancer intervention. J Cell Physiol. 2018 09; 233(9):6408-6417.

View in: PubMed
Valicenti RK, Pugh SL, Trabulsi EJ, Sartor O, Ko EC, Girvigian MR, Rosenthal SA, Shaves ME, Hoffman-Censits JH, Schallenkamp J, Sandler HM. First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy. Int J Radiat Oncol Biol Phys. 2018 03 01; 100(3):695-701.

View in: PubMed
Sorokin I, Sundaram V, Singla N, Walker J, Margulis V, Roehrborn C, Gahan JC. Robot-Assisted Versus Open Simple Prostatectomy for Benign Prostatic Hyperplasia in Large Glands: A Propensity Score-Matched Comparison of Perioperative and Short-Term Outcomes. J Endourol. 2017 11; 31(11):1164-1169.

View in: PubMed
Edmund L, Rotker KL, Lakis NS, Brito JM, Lepe M, Lombardo KA, Renzulli JF, Matoso A. Upgrading and upstaging at radical prostatectomy in the post-prostate-specific antigen screening era: an effect of delayed diagnosis or a shift in patient selection? Hum Pathol. 2017 01; 59:87-93.

View in: PubMed
Ko EC, Michaud AL, Valicenti RK. Postoperative Radiation After Radical Prostatectomy. Semin Radiat Oncol. 2017 01; 27(1):50-66.

View in: PubMed

People

Explore

Similar Concepts

Top Journals